Zydus Cadila Said In Talks To Acquire Strides, Denied By Strides CEO
This article was originally published in PharmAsia News
Executive Summary
Zydus Cadila reportedly is discussing an acquisition of Strides Arcolab’s generic-drugs business estimated to be worth more than $13 million.